Fig. 1

The lncRNA MIR181A1HG is overexpressed in CRLM, predicting poor prognosis. (a) The expression levels of MIR181A1HG in 90 CRC tissues and paired adjacent normal colorectal mucosa samples were determined by qPCR. (b) The expression levels of MIR181A1HG in CRC tissues from patients at stages I-II (n = 28) and III-IV (n = 62) were determined by qPCR. (c) qPCR analysis of the expression levels of MIR181A1HG in CRC patients without liver metastasis (NM, n = 51) and those with liver metastasis (LM, n = 39). (d) qPCR assays were used to assess MIR181A1HG expression in serum EVs from CRC patients (n = 90) and healthy controls (n = 40). (e) qPCR analysis of the expression levels of MIR181A1HG in serum EVs from CRC patients at stages I-II (n = 28) and III-IV (n = 62). (f) qPCR assays were used to evaluate MIR181A1HG expression in serum EVs from CRC patients without liver metastasis (NM, n = 51) and those with liver metastasis (LM, n = 39). (g) qPCR was used to assess MIR181A1HG expression in the serum EVs of 20 patients with CRLM before radical resection as well as one week after simultaneous resection of CRC primary tumors and LMs. Kaplan–Meier survival curves of CRC patients according to MIR181A1HG expression. CRC patients with a higher MIR181A1HG expression had obvious poorer disease-free survival (h) and overall survival (i) rates than those with low MIR181A1HG expression. Comparisons of overall survival between the MIR181A1HG-high and MIR181A1HG-low expression samples from CRC patients with (j) or without (k) LM. (***P < 0.001)